Group 1 - The core viewpoint of the news is that Huajian Medical and Renhe Pharmaceutical have established a strategic partnership to create the world's first specialized trading platform for over-the-counter (OTC) real-world assets (RWA) [1][2] - The platform will adhere to securities-level standards and aims to provide an efficient, transparent, and compliant digital trading venue for intangible assets and product rights in the OTC industry, addressing a critical gap in the global market [1][2] - Renhe Pharmaceutical, as the president unit of the China OTC Association, plays a significant role in industry policy discussions and standard-setting, leveraging its competitive position in the Chinese OTC market to lead industry development [1] Group 2 - This strategic cooperation marks a new phase for the "ETHK" blockchain financial ecosystem strategy, showcasing the innovative "ETHK global RWA trading platform" model on a global stage [2] - The collaboration reflects the company's commitment to using cutting-edge technology and rigorous compliance practices to build an open and empowering digital financial ecosystem [2] - The partnership aims to facilitate the digital transformation of classic national brands like Renhe Pharmaceutical, contributing to national industrial upgrades and the development of the digital economy [2] Group 3 - The board believes that this collaboration will generate significant synergies, positively impacting the strategic transformation and value reassessment of both companies [3] - The companies will work closely to ensure the successful launch and stable operation of the world's first OTC RWA trading platform, leveraging their combined resources [3]

Core Viewpoint - The strategic partnership between Huajian Medical and Renhe Pharmaceutical aims to establish the world's first specialized trading platform for over-the-counter (OTC) real-world assets (RWA), addressing a significant gap in the global market [1][2]. Group 1: Strategic Collaboration - The collaboration signifies a new phase in Huajian Medical's "ETHK" blockchain financial ecosystem strategy, marking the global debut of its innovative "ETHK Global RWA Exchange" business model [2]. - Renhe Pharmaceutical, as the president unit of the China OTC Association, plays a crucial role in industry policy discussions and standard-setting, leveraging its strong market position to lead the development of the OTC sector [1][2]. Group 2: Goals and Vision - The partnership reflects the commitment to create a transparent, efficient, and compliant digital trading platform for intangible assets and product rights in the OTC industry, ultimately serving the broader goal of enhancing the digital economy and national industrial upgrades [2]. - The collaboration is expected to generate significant synergies, driving strategic transformation and value reassessment for both companies, while ensuring the successful launch and operation of the OTC RWA exchange [3].

Group 1 - The company has announced a strategic partnership with Renhe Pharmaceutical's wholly-owned subsidiary, Renhe International, to establish the world's first vertical RWA exchange focused on the OTC (over-the-counter) drug sector in the United States [1]

與 仁 和 藥 業（000650.SZ） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 IVD Medical Holding Limited 華檢醫療控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1931） 全資附屬公司仁和國際達成重大戰略合作 與 仁 和 藥 業（000650.SZ）間 接 全 資 附 屬 公 司 仁 和 國 際 達 成 重 大 戰 略 合 作，於 美 國 共 同 籌 建 全 球 首 家 非 處 方 藥（OTC）垂 直 領 域RWA交 易 所。 本 公 告 乃 由 華 檢 醫 療 控 股 有 限 公 司（「本公司」或「華檢醫療」，連 同 其 附 屬 公 司 統 稱「本集團」）自 願 作 出，旨 在 向 股 東 及 潛 在 投 資 者 提 供 本 集 團 業 務 發 展 的 最 新 資 料。 一、前 言：ETHK生態戰略的系統性深化 茲提述本公司日期為2025年 ...

资料显示，仁和药业股份有限公司位于江西省南昌市红谷滩新区红谷中大道998号绿地中央广场B区元 创国际18层，成立日期1996年12月4日，上市日期1996年12月10日，公司主营业务涉及生产、销售中西 药、原料药及健康相关产品,包括口服固体制剂、口服液体制剂、大容量注射剂、小容量注射剂、外用 洗剂、搽剂、栓剂、软膏剂等剂型药品以及健康相关产品。主营业务收入构成为：药品70.25%，健康 相关产品27.79%，其他业务产品1.95%。 从仁和药业十大流通股东角度 数据显示，南方基金旗下1只基金位居仁和药业十大流通股东。南方中证1000ETF（512100）二季度增 持193.77万股，持有股数1033.67万股，占流通股的比例为0.78%。根据测算，今日浮盈赚取约351.45万 元。 9月16日，仁和药业涨5.33%，截至发稿，报6.72元/股，成交2.65亿元，换手率3.01%，总市值94.08亿 元。 南方中证1000ETF（512100）基金经理为崔蕾。 截至发稿，崔蕾累计任职时间6年315天，现任基金资产总规模949.76亿元，任职期间最佳基金回报 147.61%， 任职期间最差基金回报-15.93%。 ...

Group 1 - The company has announced the launch of the world's first Ulook AI glasses, which are currently in trial sales [2] - The official WeChat account of the subsidiary, Shining Brand, has published information regarding the Ulook AI glasses [2] - The company clarified that commercial sales of the Ulook glasses have not yet commenced [2]

Group 1 - The company has not applied for patents for the ulook smart health glasses globally [2] - The ulook smart health glasses are noted as the world's first product of its kind [2] - The inquiry was made by an investor on an interactive platform [2] Group 2 - The company involved is Renhe Pharmaceutical (000650.SZ) [2] - The response was provided on September 9 [2] - The interaction highlights investor interest in the company's innovative products [2]

Core Viewpoint - Renhe Pharmaceutical Co., Ltd. is facing significant challenges in maintaining growth due to intense competition and policy regulations in the pharmaceutical industry, as evidenced by its declining revenue and net profit in the first half of 2025 [1][3]. Financial Performance - The company reported a revenue of approximately 1.975 billion yuan in the first half of 2025, a year-on-year decrease of 16.46% [1]. - The net profit attributable to shareholders was about 290 million yuan, down 13.87% year-on-year, continuing a trend of declining performance over recent years [1][3]. - Since 2019, revenue growth has stagnated, with only a slight increase of less than 500 million yuan and net profit rising by just 29 million yuan over five years [3]. Market Challenges - The decline in performance is attributed to factors such as medical insurance cost control policies, a sluggish macroeconomic environment, and fierce competition in the pharmaceutical e-commerce sector [3]. - The health-related product segment generated revenue of 549 million yuan in the first half of 2025, reflecting a 13.4% decrease, which is even higher than the decline in the pharmaceutical segment [3][4]. Acquisition Strategy - Renhe Pharmaceutical has pursued acquisitions in the health sector since 2021, acquiring 80% stakes in seven companies, aiming to create a comprehensive health product line [3]. - However, the anticipated synergies from these acquisitions have not materialized, with revenue levels reverting to pre-acquisition figures [3][4]. Integration Challenges - The difficulties in cross-industry integration have exceeded expectations, as there are significant differences in channels, operations, and brand logic between pharmaceuticals and health consumer products [4]. - The health market has become highly competitive, with both online and offline channels saturated, making it challenging for the company to stand out despite collaborations with major e-commerce platforms [4]. Financial Health - Although the net cash flow from operating activities increased by 86.14% year-on-year, this was primarily due to reduced cash payments for goods and taxes rather than profit growth [6]. - The company's monetary funds decreased by nearly 60% compared to the end of the previous year, indicating a preference for financial management over reinvestment [6]. Future Outlook - The company is working on several projects, including the digital transformation of health and disinfection product production lines, but progress has not met expectations [6]. - The challenges faced by Renhe Pharmaceutical reflect broader difficulties in the traditional OTC pharmaceutical sector, highlighting the need for comprehensive innovation across products, channels, and organizational capabilities to achieve sustainable growth in a transforming industry [6].

Core Viewpoint - Renhe Pharmaceutical's stock has shown a positive trend with a year-to-date increase of 15.51%, reflecting strong market interest and performance in the pharmaceutical sector [1][2]. Company Overview - Renhe Pharmaceutical, established on December 4, 1996, and listed on December 10, 1996, is located in Nanchang, Jiangxi Province. The company specializes in the production and sale of traditional Chinese and Western medicines, raw materials, and health-related products [1]. - The company's revenue composition includes 70.25% from pharmaceuticals, 27.79% from health-related products, and 1.95% from other business products [1]. Financial Performance - For the first half of 2025, Renhe Pharmaceutical reported a revenue of 1.975 billion yuan, a year-on-year decrease of 16.46%, and a net profit attributable to shareholders of 290 million yuan, down 13.87% compared to the previous year [2]. - The company has distributed a total of 1.962 billion yuan in dividends since its A-share listing, with 770 million yuan distributed over the last three years [3]. Shareholder Information - As of June 30, 2025, Renhe Pharmaceutical had 104,400 shareholders, a decrease of 2.76% from the previous period. The average number of tradable shares per shareholder increased by 2.84% to 12,748 shares [2]. - Major shareholders include Hong Kong Central Clearing Limited, which holds 11.4865 million shares, and Southern CSI 1000 ETF, holding 10.3367 million shares, both of which have increased their holdings [3].

Core Viewpoint - Renhe Pharmaceutical (000650) announced on September 2 that its Ulook glasses have not yet been officially launched [1] Company Summary - Renhe Pharmaceutical is currently in the process of preparing for the launch of its Ulook glasses, indicating that the product is still in the pre-release phase [1]